Hydroxychloroquine News and Research

RSS

Why cheap, older drugs that might treat covid never get out of the lab

In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.

19 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Researchers quantified the cost-effective health benefits of pursuing further research or approving or rejecting COVID-19 drugs based on the existing research using a novel method called VOI analysis.

4 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Impact of racial disparities on COVID-19 outcomes

A new study investigated the racial disparities in COVID-19 outcomes in Black and White patients diagnosed with cancer.

31 Mar 2022

The potential efficacy of nasal nanoparticle COVID-19 vaccines

The current paper reviews progress in this field regarding nasal nanoparticle vaccines for COVID-19.

30 Mar 2022

Black patients with cancer experience worse outcomes after COVID-19 diagnosis

Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients in a study published March 28 in JAMA Network Open.

28 Mar 2022

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.

28 Mar 2022

The importance of the endosomal pathway for SARS-CoV-2 entry

Researchers demonstrated that combined inhibition of cell-surface-based and endosomal pathways completely blocked SARS-CoV-2 entry into mammalian cells.

21 Mar 2022

Malaria drug could help treat chemotherapy-resistant head and neck cancers

A new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.

14 Mar 2022

Mathematical model for evaluating factors driving SARS-CoV-2 transmission and pathogenesis

A new study provides an overview of the use of mathematical modeling to determine severe acute respiratory syndrome coronavirus 2 kinetics.

9 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

White blood cell count as a prognostic indicator of COVID-19

Based on a new study, researchers concluded WBC count variations worsen clinical outcomes such as severity, mortality, and hospital discharge rates leading to a poorer prognosis in COVID-19 patients.

23 Feb 2022

Prescribing of ineffective COVID drugs could have been influenced by political affiliation

Two treatments that have been shown to be ineffective against COVID-19—hydroxychloroquine and ivermectin—were more heavily prescribed in the latter part of 2020 in U.S. counties with a higher Republican vote share in the 2020 presidential election, according to a new research letter co-authored by researchers from Harvard T.H. Chan School of Public Health.

18 Feb 2022

Hydroxychloroquine News and Research

Why cheap, older drugs that might treat covid never get out of the lab

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Impact of racial disparities on COVID-19 outcomes

The potential efficacy of nasal nanoparticle COVID-19 vaccines

Black patients with cancer experience worse outcomes after COVID-19 diagnosis

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

The importance of the endosomal pathway for SARS-CoV-2 entry

Malaria drug could help treat chemotherapy-resistant head and neck cancers

Mathematical model for evaluating factors driving SARS-CoV-2 transmission and pathogenesis

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

White blood cell count as a prognostic indicator of COVID-19

Prescribing of ineffective COVID drugs could have been influenced by political affiliation

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Use of immunosuppressants for inflammatory rheumatic diseases and the associated risk of severe COVID-19

Medical boards pressured to let it slide when doctors spread covid misinformation

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News